CCL20 and neoplasm: However, additional factors such as GC type (e.g., intestinal-type GAC vs. diffuse GAC), tumor locations (e.g., corpus vs. antrum), and PPARδ expression levels of tumor cells (high vs. low) might need to be considered and adjusted when the significance of circulating CCL20 is evaluated as a biomarker in clinical studies.